Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 326Neoplasm Metastasis 31Advanced Breast Cancer 18Neoplasms 17Ovarian Neoplasms 11Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Prostatic Neoplasms 7Endometrial Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Breast Diseases 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms by Site 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Recurrence 3Multiple Endocrine Neoplasia Type 1 3Head and Neck Neoplasms 3Breast Neoplasm Female 3Uterine Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2Hyperglycemia 2HER2-positive Metastatic Breast Cancer 2HER2-positive Breast Cancer 2

Interventions

Cyclophosphamide 6Radiotherapy 5olaparib 3exemestane 3Paclitaxel 3Letrozole 3Itraconazole 3Gemcitabine 3Fulvestrant 3Carboplatin 3Blood Specimen Collection 3palbociclib 2fludarabine phosphate 2eribulin 2avelumab 2abemaciclib 2Therapeutics 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Mastectomy 2Flow Cytometry 2Filgrastim 2Exercise 2Everolimus 2Etoposide 2Dasatinib 2Cetuximab 2Carmustine 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × Fulvestrant × Breast × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Pfizer

Phase 2 Active not recruiting
333 enrolled
Breast

Breast Neoplasms, Recurrence

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed
514 enrolled 13 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡